BACKGROUND The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specific risk factor for cardiovascular (CV) disease has been challenged by recent clinical trials and genetic studies.
F or the past several decades, it has been widely accepted that highdensity lipoprotein cholesterol (HDL-C) plays an important role in the development of cardiovascular (CV) mortality and morbidity (1) (2) (3) (4) . Early epidemiological studies consistently demonstrated a linear inverse relationship between HDL-C levels and CV events. For example, studies have shown that each 1 mg/dl increase in HDL-C level was associated with 3% to 4% lower rates of death from cardiac causes (2, 5, 6) , suggesting that attainment of higher levels of HDL-C may reduce the risk of CV events.
However, the inability of recent randomized trials to improve clinical outcomes by attempting to increase HDL-C level has challenged this conventional wisdom (7) (8) (9) (10) (11) . Newer epidemiological and genetics studies have suggested that HDL-C level may not be predictive of CV outcomes in all subjects (12) (13) (14) (15) . Moreover, associations are known between HDL-C level and other demographic and lifestyle factors, such as smoking, obesity, and limited physical activity (2) . These data suggest that HDL-C level may be a confounded variable, and thereby question the plausibility of HDL-C level as a specific risk factor for CV disease (16) .
To the best of our knowledge, no large population-based study has evaluated the association between the full range of HDL-C levels and CV and non-CV deaths in individuals living in the same environment and exposed to the same health care system. To achieve our objectives, we used the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) cohort, which is a novel "big data" research database created by linking together multiple individual-level population-based datasets on sociodemographics, cardiac risk factors and comorbidities, laboratory values, health services, medications, and clinical outcomes in Ontario, Canada (17, 18) .
METHODS
The CANHEART cohort used in this study was created by merging 17 different individual-level data sources using encoded identifiers to ensure patient confidentiality (17, 18) . This big data source is described in detail elsewhere (17, 18) . Specific data sources essential to this current study included: 1) the (19) . Lipid testing is also recommended for individuals at any age with CV risk factors, renal insufficiency, or evidence of atherosclerosis (19) .
The primary outcome of our study was causespecific mortality. Information on cause of death was obtained from the Ontario Vital Statistics Database, which categorizes cause of death using ICD codes (17) . Deaths from CV causes were identified with ICD-10-CA I00 to I99, deaths from cancer causes were identified using C00 to D48, and the remaining codes were used to identify non-CV, noncancer causes of death. Complete follow-up data were available for each patient through December 31, 2012.
STATISTICAL ANALYSIS. The study cohort was stratified into pre-determined groups based on HDL-C levels in mg/dl (#30, 31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, 81 to 90, and >90) to allow examination of the relationship between HDL-C levels and mortality.
Overall cause-specific mortality rates were standardized by age and sex, calculated by direct standardization using the 2006 Canadian population as the reference population. Based on previous studies, the HDL-C strata 41 to 50 mg/dl in men and 51 to 60 mg/dl in women were selected as the reference ranges for comparison (20) . Analyses were stratified by sex because HDL-C levels differ in men and women in the general population. Tests of differences in characteristics across strata were performed using 1-way analysis of variance for comparing mean values of continuous variables and chi-square test for categorical variables.
Cause-specific hazard models were used to estimate the association of HDL-C levels on each of the 3 causes of death, after accounting for the other 2 causes of death as competing risks because individuals who died of a specific cause were no longer at risk of other causes of death (21, 22) . Hazard models were constructed separately in men and women. In 
RESULTS
To create the study cohort ( Figure 1 ), we began with more than 6. person-years for other deaths (Online Table 1 ). Agestandardized mortality rates for men and women according to HDL-C levels are shown in Table 2 and Figure 2 . In men, the age-standardized mortality rate was 8.1 per 1,000 person-years. Individuals at the The relationship between HDL-C cause-specific outcomes for statin users (Figure 3 ) was similar to our overall cohort in that we observed those with lower HDL-C had higher HR for cause-specific mortality.
Subjects with very high HDL-C levels were not associated with significantly higher risk of mortality. For 29,836 men and 43,606 women older than 66 years who were not prescribed statins, the relationship was similar with those prescribed statins (Online Figure 1 ).
The results of additional analyses for patients with LDL-C <100 mg/dl or $100 mg/dl (Online Figures 2   and 3) were consistent with the previous analysis that lower HDL-C levels were associated with higher HR for cause-specific mortality and subjects with very high HDL-C levels also were associated with higher risk. Additionally, we evaluated the impact of BMI, but it did not alter our overall results, as shown in Online Figure 4 .
DISCUSSION
In combining multiple clinical and administrative databases in Canada, we were able to create a Values are n or incidence rate (95% confidence interval). *Age-standardized mortality rate per 1,000 person-years calculated using the 2006 Canadian population as the standard population.
HDL-C ¼ high-density lipoprotein cholesterol.
Ko et al. CANHEART "big data" cohort to examine the relationship of HDL-C levels and cause-specific mortality in more than 630,000 individuals without previous CV conditions. This afforded a unique opportunity to extend previous knowledge by evaluating the entire spectrum of HDL-C levels in an unselected population. We found that lower HDL-C levels were associated with a progressively higher proportion of individuals who were socioeconomically disadvantaged and had less healthy lifestyle behaviors, more cardiac risk factors, and a greater burden of medical comorbidities. Even adjusting for a comprehensive list of potential confounding factors, we found that the relationship between HDL-C levels and outcomes were not linear. Instead, we found lower HDL-C levels had increased hazard of both CV and non-CV mortality, and individuals who had very high HDL-C levels also demonstrated increased hazard of non-CV mortality. This suggested that HDL-C level is a marker of poor general health and may not be an independent modifiable risk factor specifically for CV disease.
Recent studies have cast doubts about the prognostic importance of HDL-C level as a modifiable risk factor (3, 16, 24) . Trials of niacin and cholesteryl ester transfer protein inhibitors have clearly demonstrated their ability to increase HDL-C substantially (7) (8) (9) (10) (11) . However, none of these trials exhibited improved clinical outcomes compared with the placebo arms. Several contemporary studies have shown a lack of significant association of HDL-C levels and outcomes for patients on higher-intensity statins, with coronary artery disease, or who had undergone coronary artery bypass graft surgery (12, 13, 15) . Genetic studies using Mendelian randomization to examine the effect of very low HDL-C levels found no association with premature coronary heart disease (14) . Accordingly, the current focus of the HDL-C hypothesis has shifted away from absolute HDL concentrations and toward the function of HDL-C. For example, HDL-C efflux capacity has been shown to be less confounded than HDL-C levels and a strong independent marker of CV events (25).
Our finding that lower HDL-C levels were associ- found an association between HDL-C and total mortality in men. However, in contrast to our findings, that association was attenuated after adjustment for traditional CV risk factors and alcohol consumption.
The majority of previous observational studies likely lacked sufficient sample sizes to explore outcomes at a full range of HDL-C levels. The Emerging cause-specific mortality outcomes that was "U-shaped," rather than linear, as it is traditionally described. Patients whose HDL-C levels were very low (<50 mg/dl in women and <40 mg/dl in men) and very high (>80 to 90 mg/dl) experienced a greater hazard of death compared with individuals who had HDL-C levels that fell within intermediate ranges.
We are uncertain as to why higher hazard of noncardiac/noncancer mortality was observed among individuals with very high HDL-C levels. A previous study from Finland has suggested that the increased risk associated with high HDL-C levels in men might be related to increased alcohol intake (28). However, similar increased hazard was observed in our study even after adjusting for heavy alcohol use. 
Women
Use of statin therapy did not change the relationship of HDL-C levels and cause-specific outcomes from those seen in the overall cohort in patients older than 65 years. Figure 2 . The CANHEART HDL Study BMI, our overall cohort included individuals with and without obesity, and the inclusion of BMI did not alter our finding between HDL-C levels and outcomes. This additional analysis reinforces the fact that our associations were not just driven by patients with increased adiposity.
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CONCLUSIONS
In a large population-based cohort of individuals without pre-existing cardiovascular conditions, low and very high HDL-C levels were associated with a higher risk of CV mortality as well as non-CV mortality. HDL-C levels were highly correlated with many factors such as sociodemographic, lifestyle, and comorbidity factors, all of which increase the risk of adverse outcomes. These findings suggested that HDL-C level is unlikely to represent a cardiovascularspecific risk factor or a target for intervention given similarities in its associations with noncardiovascular outcomes. KEY WORDS cardiac and noncardiac death, epidemiology, outcomes, risk factor, sociodemographic APPENDIX For supplemental methods as well as a table and figures, please see the online version of this paper.
